Navigation Links
Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Date:8/12/2008

VANCOUVER, Aug. 12 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received CE Mark approval to begin marketing the HemoStream(TM) Chronic Dialysis Catheter in Europe.

This CE Mark approval follows Angiotech's announcement in August 2007 that it had received clearance from the U.S. Food and Drug Association (FDA) to begin marketing HemoStream in the United States. In April of the same year, Angiotech entered into an agreement with Rex Medical, LP that granted Angiotech an exclusive license to market and distribute HemoStream worldwide.

"This CE Mark approval is another example of the international acceptance of Angiotech's technologies. With Rex Medical as our worldwide licensing partner, we look forward to expanding HemoStream's availability in Europe as well as in the United States," said Dr. William Hunter, President and CEO of Angiotech.

About the HemoStream Chronic Dialysis Catheter

Incidences of End Stage Renal Disease (ESRD) requiring dialysis are a rapidly growing challenge in healthcare worldwide. When kidneys fail, function of the kidneys can be partially replaced using a process called hemodialysis. This process involves drawing blood out of the body, filtering it through a large machine and then returning filtered blood back to the body. Chronic dialysis catheters, such as HemoStream, are used as long-term vascular access for hemodialysis. HemoStream may also be used as a temporary access while more permanent options mature or become ready for use, such as surgically created AV fistulas.

About Rex Medical, LP

Rex Medical, LP, based in Conshohocken, PA, is a priva
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Angiotech wins before the UK House of Lords
2. Angiotech to Establish Separate Operating and Royalty Businesses
3. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
4. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
5. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
6. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
7. Angiotech appoints Hank McKinnell to its Board of Directors
8. Angiotech to participate in Bank of America Health Care Conference
9. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
10. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
11. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Weekend Weather Prompts Air Quality Advisories 54577 1Weekend Weather Prompts Air Quality Advisories 54577 2Weekend Weather Prompts Air Quality Advisories 54577 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 1The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 2The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 4The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 2Senetek PLC Reports Second Quarter 2009 Financial Results 54573 3Senetek PLC Reports Second Quarter 2009 Financial Results 54573 4Senetek PLC Reports Second Quarter 2009 Financial Results 54573 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 6
GenomePlex Whole Genome Amplification (WGA) kit from Sigma-Aldrich
FluoroGuard Antifade Reagent from Bio-Rad
...n: The greater incorporation of Br-dUTP results in... using a fluorescein-labeled anti-BrdU antibody. ...he kit to counterstain the total DNA. Features and...ting in improved detection than found by using bio...
Mouse Anti-Human FBXO24 Monoclonal Antibody, Unconjugated, Clone 7F12 from Abnova Corporation
Biology Products: